Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 2Thoracic 1Sarcoma 1Dermatologic 1

Conditions

Sarcoma 286Gliosarcoma 149Glioblastoma 149Brain Neoplasms 90Osteosarcoma 84Glioma 68Gastrointestinal Stromal Tumors 68Rhabdomyosarcoma 65Lymphoma, Non-Hodgkin 59Astrocytoma 59Recurrence 57Dendritic Cell Sarcoma, Interdigitating 57Sarcoma, Ewing 55Neoplasms 54Precursor Cell Lymphoblastic Leukemia-Lymphoma 50Lymphoma 50Burkitt Lymphoma 49Central Nervous System Neoplasms 48Neuroblastoma 47Lymphoma, Large B-Cell, Diffuse 47Lymphoma, Follicular 46Neoplasm Metastasis 45Lymphoma, Mantle-Cell 45Leiomyosarcoma 44Oligodendroglioma 43Leukemia, Myeloid, Acute 43Liposarcoma 42Lymphoma, B-Cell, Marginal Zone 41Leukemia, Lymphocytic, Chronic, B-Cell 41Hodgkin Disease 41

Interventions

Lenalidomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Erdheim-Chester Disease × Sarcoma × Clear all
NCT02523040 2025-12-10

Lenalidomide for Adult Histiocyte Disorders

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
12 enrolled 14 charts
MyeloidSarcoma

Histiocytosis, Langerhans-Cell, Erdheim-Chester Disease, Histiocytic Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡